Q1 EPS Estimates for Kodiak Sciences Cut by HC Wainwright

Kodiak Sciences Inc. (NASDAQ:KOD) – Equities research analysts at HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for shares of Kodiak Sciences in a research note issued on Wednesday, April 1st. HC Wainwright analyst M. Caufield now expects that the company will post earnings of ($0.94) per share for the quarter, down from their prior estimate of ($0.75). HC Wainwright currently has a “Buy” rating and a $58.00 price target on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences’ Q2 2026 earnings at ($0.96) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.85) EPS, FY2026 earnings at ($3.56) EPS, FY2027 earnings at ($3.19) EPS, FY2028 earnings at ($1.94) EPS, FY2029 earnings at $0.19 EPS and FY2030 earnings at $3.05 EPS.

Kodiak Sciences (NASDAQ:KOD) last issued its earnings results on Tuesday, March 31st. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02).

Other equities analysts have also issued reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Kodiak Sciences in a research report on Thursday, January 22nd. UBS Group upped their target price on shares of Kodiak Sciences from $50.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, March 27th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $35.43.

Kodiak Sciences Stock Down 5.1%

Shares of KOD opened at $40.63 on Friday. Kodiak Sciences has a twelve month low of $1.92 and a twelve month high of $45.60. The stock has a market cap of $2.51 billion, a PE ratio of -9.41 and a beta of 2.39. The business’s 50-day moving average price is $26.08 and its 200-day moving average price is $22.62.

Institutional Investors Weigh In On Kodiak Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of KOD. Boone Capital Management LLC purchased a new position in Kodiak Sciences in the 3rd quarter worth approximately $11,719,000. TD Asset Management Inc bought a new stake in shares of Kodiak Sciences during the 3rd quarter worth $992,000. Campbell & CO Investment Adviser LLC purchased a new position in Kodiak Sciences in the third quarter worth $488,000. Panagora Asset Management Inc. increased its stake in Kodiak Sciences by 28.5% in the second quarter. Panagora Asset Management Inc. now owns 131,122 shares of the company’s stock valued at $489,000 after acquiring an additional 29,113 shares during the last quarter. Finally, Fox Run Management L.L.C. bought a new position in Kodiak Sciences in the third quarter valued at $204,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Company reported advancing pipeline and strong Phase III data for Zenkuda that management highlighted alongside Q4/2025 results — this progress and accelerated regulatory planning support upside expectations for KOD. Kodiak Announces Q4 and FY2025 Results
• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $58 price target even as it trimmed forecasts — that continued analyst endorsement can provide investor support and a clear upside reference point.
• Neutral Sentiment: Q4 results showed a wider-than-expected loss, but commentary focused investor attention on pipeline milestones rather than only near-term P&L metrics. Zacks: Q4 Loss Wider Than Expected
• Negative Sentiment: Multiple analysts (Lifesci Capital and HC Wainwright) cut near-term EPS estimates across Q1–Q4 2026 and lowered FY2026–FY2029/2030 forecasts — these downward revisions increase short-term earnings uncertainty and can pressure the stock. (Market commentary and analyst notes issued April 1)
• Negative Sentiment: Some cuts are large and extend into multi-year forecasts (HC Wainwright cut FY2026–FY2029/2030 estimates; Lifesci trimmed FY2026), signaling analysts see a longer recovery path to profitability — this raises risk for investors focused on near-term fundamentals.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.